Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg)
-
Carolina O. Ramos
Abstract
Objectives
Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the follow-up of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg).
Methods
Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25 mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH).
Results
At the diagnosis of CPP, the mean chronological age (CA) was 8.2 ± 1.13 year, and mean bone age (BA) was 10.4 ± 1.4 year. Mean height SDS at the start and the end of GnRHa treatment was 1.6 ± 0.8 and 1.3 ± 0.9, respectively. The mean duration of GnRHa treatment was 2.8 ± 0.8 year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2 ± 8.6 and 164.4 ± 7.3 cm, respectively (p<0.05). The mean AH was 163.2 ± 6.2 cm (mean SDS: 0.1 ± 1). All patients were within their target height (TH) range. There was a decrease in the percentage of overweight and obesity from the diagnosis until AH (39–19% p>0.05). At the AH, the insulin resistance and high LDL levels were identified in 3/17 patients (17.6%) and 2/21 patients (9.5%), respectively. The mean CA of menarche was 12.2 ± 0.5 years. At the AH, PCOS was diagnosed in one patient (4.8%).
Conclusions
Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes.
-
Research funding: There was no funding for this research
-
Author contribution: Carolina O. Ramos contributed to the collection of clinical and laboratory data, analysis of results, and writing of the manuscript. Carlos E. Seraphim, Aline G. Farias Flavia R. Tinano, and Aline G. contributed to the collection of clinical and laboratory data. Ana P. M. Canton, Berenice B. Mendonca, and Ana C. Latronico contributed to the analysis of results and revision of the manuscript. Vinicius N. Brito contributed to the design of the study, analysis of results, statistical analysis, and final revision.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The study was approved by the Hospital das Clinicas Ethics Committee (CAPPesq; approval number 1.385.131).
References
1. Latronico, AC, Brito, VN, Carel, JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016;4:265–74. https://doi.org/10.1016/s2213-8587(15)00380-0.Search in Google Scholar
2. Lahlou, N, Carel, JC, Chaussain, JL, Roger, M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000;13:723–37. https://doi.org/10.1515/jpem.2000.13.s1.723.Search in Google Scholar PubMed
3. Mostafa, NM, Hosmane, B, Larsen, LM, Chwalisz, K, Chiu, YL, Pradhan, RS. Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty. Clin Drug Invest 2014;34:441–8. https://doi.org/10.1007/s40261-014-0193-2.Search in Google Scholar PubMed
4. Carel, JC, Lahlou, N, Jaramillo, O, Montauban, V, Teinturier, C, Colle, M, et al.. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111–6. https://doi.org/10.1210/jc.2001-020243.Search in Google Scholar PubMed
5. Lee, PA, Klein, K, Mauras, N, Neely, EK, Bloch, CA, Larsen, L, et al.. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572–80. https://doi.org/10.1210/jc.2011-2704.Search in Google Scholar PubMed
6. Lee, PA, Klein, K, Mauras, N, Lev-Vaisler, T, Bacher, P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab 2014;99:3153–9. https://doi.org/10.1210/jc.2013-4471.Search in Google Scholar PubMed
7. Eugster, EA. Treatment of central precocious puberty. J Endocr Soc 2019;3:965–72. https://doi.org/10.1210/js.2019-00036.Search in Google Scholar PubMed PubMed Central
8. Fuld, K, Chi, C, Neely, EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159:982–7.e1. https://doi.org/10.1016/j.jpeds.2011.05.036.Search in Google Scholar PubMed
9. Fuqua, JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198–207. https://doi.org/10.1210/jc.2013-1024.Search in Google Scholar PubMed
10. Durand, A, Tauber, M, Patel, B, Dutailly, P. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-release formulation. Horm Res Paediatr 2017;87:224–32. https://doi.org/10.1159/000456545.Search in Google Scholar PubMed
11. Chiocca, E, Dati, E, Baroncelli, GI, Cassio, A, Wasniewska, M, Galluzzi, F, et al.. Central precocious puberty: treatment with triptorelin 11.25 mg. Sci World J 2012;2012:583751. https://doi.org/10.1100/2012/583751.Search in Google Scholar PubMed PubMed Central
12. Badaru, A, Wilson, DM, Bachrach, LK, Fechner, P, Gandrud, LM, Durham, E, et al.. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862–7. https://doi.org/10.1210/jc.2005-1500.Search in Google Scholar PubMed
13. Carel, JC, Blumberg, J, Seymour, C, Adamsbaum, C, Lahlou, N, Group T-mCS. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119–24. https://doi.org/10.1530/eje.1.02056.Search in Google Scholar PubMed
14. Partsch, CJ, Heger, S, Sippell, WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002;56:129–48. https://doi.org/10.1046/j.0300-0664.2001.01490.x.Search in Google Scholar PubMed
15. Lazar, L, Padoa, A, Phillip, M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483–9. https://doi.org/10.1210/jc.2007-0321.Search in Google Scholar PubMed
16. Carel, JC, Lahlou, N, Roger, M, Chaussain, JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135–47. https://doi.org/10.1093/humupd/dmh012.Search in Google Scholar PubMed
17. Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, Antoniazzi, F, et al.. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752–62. https://doi.org/10.1542/peds.2008-1783.Search in Google Scholar PubMed
18. Brito, VN, Latronico, AC, Cukier, P, Teles, MG, Silveira, LF, Arnhold, IJ, et al.. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008;93:2662–9. https://doi.org/10.1210/jc.2007-2183.Search in Google Scholar PubMed
19. Bertelloni, S, Massart, F, Einaudi, S, Wasniewska, M, Miccoli, M, Baroncelli, GI. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr 2015;84:396–400. https://doi.org/10.1159/000441497.Search in Google Scholar PubMed
20. Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international Consortium. Horm Res Paediatr 2019;91:357–72. https://doi.org/10.1159/000501336.Search in Google Scholar PubMed
21. Brito, VN, Spinola-Castro, AM, Kochi, C, Kopacek, C, Silva, PC, Guerra-Júnior, G. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab 2016;60:163–72. https://doi.org/10.1590/2359-3997000000144.Search in Google Scholar PubMed
22. Marshall, WA, Tanner, JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303. https://doi.org/10.1136/adc.44.235.291.Search in Google Scholar PubMed PubMed Central
23. Brito, VN, Batista, MC, Borges, MF, Latronico, AC, Kohek, MB, Thirone, AC, et al.. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 1999;84:3539–44. https://doi.org/10.1210/jcem.84.10.6024.Search in Google Scholar PubMed
24. Freire, AV, Escobar, ME, Gryngarten, MG, Arcari, AJ, Ballerini, MG, Bergadá, I, et al.. High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls. Clin Endocrinol 2013;78:398–404. https://doi.org/10.1111/j.1365-2265.2012.04517.x.Search in Google Scholar PubMed
25. Greulich, WW, Pyle, SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford: Stanford University Press; 1959.10.1097/00000441-195909000-00030Search in Google Scholar
26. Bayley, N, Pinneau, SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–41. https://doi.org/10.1016/s0022-3476(52)80205-7.Search in Google Scholar PubMed
27. Abreu, AP, Dauber, A, Macedo, DB, Noel, SD, Brito, VN, Gill, JC, et al.. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med 2013;368:2467–75. https://doi.org/10.1056/nejmoa1302160.Search in Google Scholar PubMed PubMed Central
28. Dauber, A, Cunha-Silva, M, Macedo, DB, Brito, VN, Abreu, AP, Roberts, SA, et al.. Paternally inherited DLK1 deletion associated with familial central precocious puberty. J Clin Endocrinol Metab 2017;102:1557–67. https://doi.org/10.1210/jc.2016-3677.Search in Google Scholar PubMed PubMed Central
29. Legro, RS, Arslanian, SA, Ehrmann, DA, Hoeger, KM, Murad, MH, Pasquali, R, et al.. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565–92. https://doi.org/10.1210/jc.2013-2350.Search in Google Scholar PubMed PubMed Central
30. Ibáñez, L, Oberfield, SE, Witchel, S, Auchus, RJ, Chang, RJ, Codner, E, et al.. An international Consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017;88:371–95. https://doi.org/10.1159/000479371.Search in Google Scholar PubMed
31. Klein, KO, Freire, A, Gryngarten, MG, Kletter, GB, Benson, M, Miller, BS, et al.. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty. J Clin Endocrinol Metab 2020;105. https://doi.org/10.1210/clinem/dgaa479.Search in Google Scholar PubMed PubMed Central
32. Vatopoulou, A, Roos, E, Daniilidis, A, Dinas, K. Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months. Gynecol Endocrinol 2020;36:1–3. https://doi.org/10.1080/09513590.2020.1770723.Search in Google Scholar PubMed
33. Lazar, L, Meyerovitch, J, de Vries, L, Phillip, M, Lebenthal, Y. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol 2014;80:570–6. https://doi.org/10.1111/cen.12319.Search in Google Scholar PubMed
34. Lazar, L, Lebenthal, Y, Yackobovitch-Gavan, M, Shalitin, S, de Vries, L, Phillip, M, et al.. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab 2015;100:1445–51. https://doi.org/10.1210/jc.2014-3748.Search in Google Scholar PubMed
35. Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management OF endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79–87. https://doi.org/10.1530/eje-15-0590.Search in Google Scholar
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review Article
- An endocrine perspective on menstrual suppression for adolescents: achieving good suppression while optimizing bone health
- Original Articles
- Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg)
- Evaluation of the resilience of the girls with central precocious puberty treated with gonadotropin-releasing hormone analog
- The effect of GnRH stimulation on AMH regulation in central precocious puberty and isolated premature thelarche
- Association of the apoptotic marker APO1/Fas with children’s predisposing factors for metabolic syndrome and with mean platelet volume
- Serum adiponectin, body adiposity and metabolic parameters in obese Egyptian children with Down syndrome
- Urinary iodine and thyroglobulin are useful markers in infants suspected of congenital hypothyroidism based on newborn screening
- Comparison of plasmapheresis with medical apheresis in terms of efficacy and cost in the acute treatment of hypertriglyceridemia in children with lipoprotein lipase deficiency
- Clinical, biochemical and genotypical characteristics in biotinidase deficiency
- High uric acid levels in overweight and obese children and their relationship with cardiometabolic risk factors: what is missing in this puzzle?
- Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation
- Determinants of ultra-processed food consumption in Brazilian children and adolescents with type 1 diabetes mellitus: a cross-sectional study
- The prevalence, immune profile, and clinical characteristics of children with celiac disease and type 1 diabetes mellitus in the state of Qatar
- Case Reports
- A rare and preventable aetiology of neurodevelopmental delay and epilepsy: familial glucocorticoid deficiency
- Giant plurihormonal pituitary adenoma in a child – case study
- The usefulness of copeptin for the diagnosis of nephrogenic diabetes insipidus in infancy: a case report
- A novel synonymous homozygous variant [c.2538G>A (p.Thr846Thr)] in TRPM6 in a patient with hypomagnesemia with secondary hypocalcemia
- Idiopathic juvenile osteoporosis in a child: a four-year follow-up with review of literature
Articles in the same Issue
- Frontmatter
- Review Article
- An endocrine perspective on menstrual suppression for adolescents: achieving good suppression while optimizing bone health
- Original Articles
- Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg)
- Evaluation of the resilience of the girls with central precocious puberty treated with gonadotropin-releasing hormone analog
- The effect of GnRH stimulation on AMH regulation in central precocious puberty and isolated premature thelarche
- Association of the apoptotic marker APO1/Fas with children’s predisposing factors for metabolic syndrome and with mean platelet volume
- Serum adiponectin, body adiposity and metabolic parameters in obese Egyptian children with Down syndrome
- Urinary iodine and thyroglobulin are useful markers in infants suspected of congenital hypothyroidism based on newborn screening
- Comparison of plasmapheresis with medical apheresis in terms of efficacy and cost in the acute treatment of hypertriglyceridemia in children with lipoprotein lipase deficiency
- Clinical, biochemical and genotypical characteristics in biotinidase deficiency
- High uric acid levels in overweight and obese children and their relationship with cardiometabolic risk factors: what is missing in this puzzle?
- Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation
- Determinants of ultra-processed food consumption in Brazilian children and adolescents with type 1 diabetes mellitus: a cross-sectional study
- The prevalence, immune profile, and clinical characteristics of children with celiac disease and type 1 diabetes mellitus in the state of Qatar
- Case Reports
- A rare and preventable aetiology of neurodevelopmental delay and epilepsy: familial glucocorticoid deficiency
- Giant plurihormonal pituitary adenoma in a child – case study
- The usefulness of copeptin for the diagnosis of nephrogenic diabetes insipidus in infancy: a case report
- A novel synonymous homozygous variant [c.2538G>A (p.Thr846Thr)] in TRPM6 in a patient with hypomagnesemia with secondary hypocalcemia
- Idiopathic juvenile osteoporosis in a child: a four-year follow-up with review of literature
